Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Kohn

Showing results (331-340 of 369) with videos related to

Pageof 37
Sort By:
Cancer Research|March 17, 2006
10th Biennial Helene Harris Memorial Trust meetingFrances R Balkwill, Alan Ashworth, Robert C Bast, et al.
Journal of the National Cancer Institute|May 21, 2014
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analysesJung-Min Lee, John L Hays, Christina M Annunziata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2020
PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineWilliam P Tew, Christina Lacchetti, Annie Ellis, et al.
Journal of the National Cancer Institute|February 18, 2026
Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer typesBradley R Corr, Kara D Romano, Michael D Toboni, et al.
Gynecologic Oncology|February 15, 2003
Specific keynote: molecular therapeutics in ovarian cancerGordon B Mills, Xianjun Fang, Yiling Lu, et al.
Frontiers in Oncology|June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian CancerJung-Min Lee, Jane B Trepel, Peter Choyke, et al.
Cancer|November 14, 2015
Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancerAnne M Noonan, Kristen P Bunch, Jin-Qiu Chen, et al.
Oncotarget|November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung-Min Lee, John L Hays, Victoria L Chiou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancerJ F Liu, W T Barry, M Birrer, et al.
The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.
Pageof 37

Showing results (331-340 of 369) with videos related to

Sort By:
Pageof 37
Cancer Research|March 17, 2006
10th Biennial Helene Harris Memorial Trust meetingFrances R Balkwill, Alan Ashworth, Robert C Bast, et al.
Journal of the National Cancer Institute|May 21, 2014
Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analysesJung-Min Lee, John L Hays, Christina M Annunziata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2020
PARP Inhibitors in the Management of Ovarian Cancer: ASCO GuidelineWilliam P Tew, Christina Lacchetti, Annie Ellis, et al.
Journal of the National Cancer Institute|February 18, 2026
Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer typesBradley R Corr, Kara D Romano, Michael D Toboni, et al.
Gynecologic Oncology|February 15, 2003
Specific keynote: molecular therapeutics in ovarian cancerGordon B Mills, Xianjun Fang, Yiling Lu, et al.
Frontiers in Oncology|June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian CancerJung-Min Lee, Jane B Trepel, Peter Choyke, et al.
Cancer|November 14, 2015
Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancerAnne M Noonan, Kristen P Bunch, Jin-Qiu Chen, et al.
Oncotarget|November 8, 2017
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerJung-Min Lee, John L Hays, Victoria L Chiou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 13, 2019
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancerJ F Liu, W T Barry, M Birrer, et al.
The Lancet. Oncology|January 24, 2018
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 studyJung-Min Lee, Jayakumar Nair, Alexandra Zimmer, et al.
Pageof 37